Syndicated Research Studies

AI In Oncology Market Overview The AI in oncology market was valued at USD 6.0 billion in 2025. It is estimated at USD 8.3 billion in 2026 and is projected to reach USD 38.9 billion by 2033, a CAGR of 24.8% from 2026 to 2033. That is roughly a 4.7x expansion in seven years, and it signals that AI is becoming a core layer of cancer care rather than an experimental add-on. North America led in 2025 with a 45.8% revenue share, while Asia Pacific is expected to grow the fastest. Key Market Dynamics & Segments The market is segmented by component type, cancer type, application, end use and region. Each segment has a clear leader today and a different segment growing faster behind it. Component type. Hardware led in 2025 with a 39.4% share. AI is embedded in imaging systems and medical devices that providers already buy, so hardware captured the early revenue. Software solutions are expected to grow fastest from 2026 to 2033. Software tools predict brain, breast, liver, lung and pr...

Cancer diagnosis used to hinge almost entirely on the trained eye of a radiologist or pathologist, working scan by scan, slide by slide. That model is now being layered — not replaced, but sharpened — by algorithms that can flag a suspicious lesion in milliseconds or predict a chemotherapy dose from a CT scan's fat, bone, and muscle composition. That shift is exactly what's fueling the AI in oncology market , valued at USD 6.0 billion in 2025 and on track to hit USD 38.9 billion by 2033, expanding at a CAGR of 24.8% from 2026 onward. Numbers this steep usually signal one of two things: a speculative bubble, or a genuine infrastructure shift in how an entire discipline operates. Cancer AI looks far closer to the second. Every major driver behind this growth — rising cancer incidence, FDA clearances crossing the 690-device mark, precision-medicine adoption — points to a field embedding AI into its clinical backbone rather than experimenting at the margins. What's...